Cite
HARVARD Citation
Bujarski, S. et al. (2022). Use of serum B‐cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone. Hematological oncology. 40 (2), pp. 243-248. [Online].